top of page

Search Results

334 results found for "Keltic Pharma Therapeutics"

Programs (1)

View All

Posts (259)

  • ShouTi Pharma has a brand new website

    January 2022 "We are an experienced, innovative, global team on a bold mission to improve health by creating and developing life-changing medicines for people around the world." Read more at the source #DrGPCR #GPCR #IndustryNews

  • AELIS PHARMA launches their IPO for €25 million

    February 2022 "We are proud to announce the success of our IPO! Thank you to our shareholders, both historical and new, for their trust. The €25 million fundraising gives us the means to achieve our ambitions: to become a leading player in the field of brain diseases! #IPO #biotech #innovation #traitements #addiction #cannabis #Trisomie21 #Downsyndrome" Read more at the source #DrGPCR #GPCR #IndustryNews

  • Inversago Pharma appoints Glenn S. Vraniak as Chief Financial Officer

    May 2022 "MONTREAL (CANADA) – May 17, 2022 – Inversago Pharma Inc.

View All

Other Pages (72)

  • Ep 79 with Dr. Graeme Milligan

    Milligan is the co-founder of both Caldan Therapeutics (2015) which discovers novel therapeutics for and other indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma Therapeutics (2020) which is developing new treatments for malaria.

  • Ep 37 with Dr. Samuel Hoare

    company supporting pharmaceutical, life science, and academic scientists in the development of new therapeutics As an industry pharmacologist, he consults with numerous pharma and biotechs in understanding and applying analysis of drug action and is known for applying binding kinetics to the development of effective therapeutics

  • Ep 152 with Dr Arthur Christopoulos

    Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics They explored the evolution of the field, allosteric modulation concepts, and potential therapeutic approaches Arthur will work on designing ligands for specific receptors, aiming to create biased agonists for therapeutic Yamina discussed the potential of autoantibodies and allosteric modulation in the context of disease and therapeutic endogenous allosteric ligands and the possibility of using a neutral allosteric ligand as a preferred therapeutic

View All

Events (2)

View All

Powered by


All Rights Reserved © 2020 - 2024

Dr. GPCR CORP is a 501(c)(3) non profit organization

  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
bottom of page